Jacalyn Rosenblatt
Deputy Director, Immunotherapy Institute · Beth Israel Deaconess Medical Center
Credentials: · · · ·
History
- Present
Immunotherapy Institute Center · Beth Israel Deaconess Medical Center
- 2000–2001
Hematology
- 1997–2000
Internal Medicine
- 1993–1997
Doctor of Medicine
Research
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
New England Journal of Medicine · 2019 · 1,419 citations
PML targeting eradicates quiescent leukaemia-initiating cells
Nature · 2008 · 455 citations
Journal of Immunotherapy · 2011 · First of 13 authors · Corresponding · 247 citations
70 papers
- DK
25 papers
- RJ
15 papers
- AP
13 papers
13 papers
- JL
12 papers
12 papers
- MN
12 papers · 5 as a fellow
Grants
- 2021–2026
Personalized Adoptive T-Cell Therapy for AML
National Cancer Institute · R01
PI · $3.6M · Beth Israel Deaconess Medical Center
- 2010–2013
Dendritic Cell/Leukemia Fusions and PD-1 Blockade for AML
National Cancer Institute · R21
Contact PI · $729.4K · Beth Israel Deaconess Medical Center
Clinical trials
- 2026–2032
DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM
Principal investigator · Recruiting · Phase 1
David Avigan
- 2020
Abatacept for Patients With COVID-19 and Respiratory Distress
Principal investigator · Withdrawn · Phase 1, Phase 2
Beth Israel Deaconess Medical Center
- 2019–2021
Principal investigator · Terminated · Phase 2
Beth Israel Deaconess Medical Center
- 2018–2026
Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients
Principal investigator · Active not recruiting · Phase 1
Beth Israel Deaconess Medical Center